title: Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study.
abstract: OBJECTIVE
  To determine whether UK patients with coronary heart disease (CHD) who also have schizophrenia or bipolar disorder are less likely to receive primary care in accordance with the agreed national standards of the UK than patients without these mental health problems.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  485 UK general practices contributing anonymised medical records of over 3.26 million patients to the QRESEARCH database.
  
  
  METHODS
  127,932 patients with CHD of whom 701 had a diagnosis of schizophrenia or bipolar disorder.
  
  
  METHODS
  The relative risks of receiving statin medication and each of the CHD care indicators defined in the UK General Medical Services contract, for patients with schizophrenia or bipolar disorder compared with patients with neither condition. The results were adjusted for age, sex, deprivation, diabetes, stroke and smoking status, and allowed for clustering by practice.
  
  
  RESULTS
  Patients with schizophrenia were 15% less likely to have a recent prescription for a statin (95% CI 8% to 20%) and 7% less likely to have a recent record of cholesterol level (95% CI 3% to 11%). There were no significant differences in the adjusted analyses between mental health groups on recording smoking status, advising on smoking cessation, recording blood pressure, achieving target blood pressure or cholesterol values, or prescribing aspirin, antiplatelets, anticoagulants or beta blockers.
  
  
  CONCLUSIONS
  Although the majority of CHD care indicators are achieved equally for patients who also have a serious mental health problem, there is a shortfall in identifying and treating raised cholesterol among patients with schizophrenia, despite their higher level of risk factors.
authors.affiliation: Division of Primary Care, University of Nottingham, Nottingham, UK. julia.hippisley-cox@nottingham.ac.uk
authors.forename: Julia
authors.initials: J
authors.lastname: Hippisley-Cox
authors.forename: Chris
authors.initials: C
authors.lastname: Parker
authors.forename: Carol
authors.initials: C
authors.lastname: Coupland
authors.forename: Yana
authors.initials: Y
authors.lastname: Vinogradova
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D003327:Coronary Disease / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D003430:Cross-Sectional Studies; D005260:Female; D006297:Health Services Accessibility / Q000592:standards*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D001523:Mental Disorders / Q000150:complications / Q000628:therapy*; D008875:Middle Aged; D011320:Primary Health Care / Q000458:organization & administration*; D012307:Risk Factors; D017678:Sex Distribution; D012959:Socioeconomic Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors